



# Mouse anti-Mouse ABL monoclonal antibody, clone 9F0 (CABT-B9171)

This product is for research use only and is not intended for diagnostic use.

## PRODUCT INFORMATION

<b>Immunogen</b>	Recombinant Mouse Abl Gag Fusion Protein
<b>Isotype</b>	IgG1
<b>Source/Host</b>	Mouse
<b>Species Reactivity</b>	Dog, Human, Mouse, Rat, Chicken, Frog
<b>Clone</b>	9F0
<b>Purification</b>	The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.
<b>Conjugate</b>	Unconjugated
<b>Applications</b>	WB; IF; IP
<b>Format</b>	Liquid
<b>Concentration</b>	0.5 mg/ml
<b>Size</b>	100 µg
<b>Buffer</b>	Aqueous buffered solution containing ≤0.09% sodium azide.
<b>Storage</b>	Store undiluted at -20°C.

## BACKGROUND

<b>Introduction</b>	The proto-oncogene c-abl was first isolated from the mouse genome as a gene with similarity to
---------------------	--

the v-abl oncogene of Abelson murine leukemia virus. The c-abl gene encodes a protein tyrosine kinase that is localized in the cytoplasm and nucleus. The c-abl protein shares several common features with other cytoplasmic tyrosine kinases, including the src-homology domains 2 (SH2) and 3 (SH3). The SH2 domain is believed to bind specifically to tyrosine residues of other proteins. The function of the SH3 domain is still unclear. Unique to the c-abl tyrosine kinase is a large C-terminal segment which seems to be essential for its biological function, since mice homozygous for a C-terminal deletion of c-abl have multiple defects at birth. The C-terminal fragment of c-abl contains a DNA-binding domain, and the DNA-binding affinity of this domain seems to be regulated by phosphorylation of critical serine/threonine residues. The c-abl proto-oncogene can be activated in a variety of ways. For example, in Philadelphia chromosome (Ph1)-positive leukemias the c-abl proto-oncogene on chromosome 9 becomes fused to the bcr gene on chromosome 22, and bcr-abl fusion proteins are produced. Ph1-positive cells express either the a-typical 210 kDa bcr-abl fusion protein or a smaller 185 kDa bcr-abl fusion protein. The bcr sequences activate the c-abl tyrosine kinase by deregulating its expression, and actin filament-binding function associated with c-abl is also activated. Expression of bcr-abl fusion proteins in vitro leads to transformation of pre-B lymphoid cells supporting their role as an oncogene. The phosphorylated form of c-abl is observed at ~145 kDa on SDS/PAGE. The 8E9 clone has been reported to react with an epitope in the tyrosine kinase domain of murine abl proteins [Wang et al.].

This antibody is routinely tested by western blot analysis. Other applications were tested at BD Biosciences Pharmingen during antibody development only or reported in the literature.

---

<b>Keywords</b>	ABL1; c-abl oncogene 1, non-receptor tyrosine kinase; ABL; JTK7; p150; c-ABL; v-abl; c-ABL1; bcr/abl; tyrosine-protein kinase ABL1; proto-oncogene c-Abl; bcr/c-abl oncogene protein; Abelson tyrosine-protein kinase 1; c-abl oncogene 1, receptor tyrosine kinase; proto-oncogene tyrosine-protein kinase ABL1; v-abl Abelson murine leukemia viral oncogene homolog 1;
-----------------	---

---

## GENE INFORMATION

---

Entrez Gene ID	<a href="#">25</a>
UniProt ID	<a href="#">P00519</a>

---